2022 World Conference on Lung Cancer (ePosters)-EP08.02-172. Effect of EGFR Inhibition on Bone Health in NSCLC Patients without Skeletal Metastasis

EP08.02-172. Effect of EGFR Inhibition on Bone Health in NSCLC Patients without Skeletal Metastasis

Pdf Summary

A retrospective study was conducted in Italy to investigate the effects of Epidermal Growth Factor Receptor (EGFR) inhibition on bone health in patients with metastatic non-small cell lung cancer (NSCLC) without bone metastases. The study included patients who were treated with EGFR-specific tyrosine kinase inhibitors (EGFR-TKIs). <br /><br />The study found that EGFR-TKIs had a low incidence of skeletal-related events (SREs), which was comparable to that expected in the general population. The different generations of EGFR-TKIs were equally safe in terms of SREs. <br /><br />A total of 13.4% of the patients experienced vertebral fractures, with the majority being mild fractures. Corticosteroid therapy was found to be associated with morphometric fractures, while EGFR-TKIs had no impact. However, the presence of morphometric fractures did not affect overall survival. <br /><br />The study highlights the importance of monitoring bone health in patients treated with EGFR-TKIs, especially those receiving corticosteroid therapy. It also suggests that EGFR inhibition does not significantly alter bone metabolism and health in NSCLC patients without skeletal metastasis. <br /><br />This study adds to the existing knowledge about the effects of EGFR inhibition on bone homeostasis and provides evidence for the safety of EGFR-TKIs in terms of bone health. Further research is needed to fully understand the long-term effects of EGFR-TKIs on bone metabolism and to identify strategies to minimize the risk of fractures in these patients.

Asset Subtitle

Marcella Mandruzzato

Meta Tag

Speaker Marcella Mandruzzato

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

retrospective study

Italy

EGFR inhibition

bone health

NSCLC

EGFR-TKIs

skeletal-related events

vertebral fractures

corticosteroid therapy

bone metabolism